Breaking News, Collaborations & Alliances

Bayer to Pay up to $4B for Gene Therapy Firm AskBio

Purchase includes an established CDMO, lays the foundation for future partnerships in the area of AAV therapies.

By: Contract Pharma

Contract Pharma Staff

Bayer AG has acquired Asklepios BioPharmaceutical, Inc. (AskBio) for $2 billion upfront and potential success-based milestone payments of up to $2 billion.   The U.S.-headquartered biopharma specializes in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters